Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R78C + RH5.1/Matrix-M malaria vaccine challenge study
ISRCTN20573724Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Jun 2026
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of R78C, RH5.1 and Matrix M in malaria (2 arms), sponsored by University of Oxford. Primary endpoints: Solicited local and systemic adverse events, Unsolicited adverse events and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
R78CRH5.1Matrix M
03
Conditions
malaria
Beyond the preview
Go deeper on ISRCTN20573724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20573724.